RegenLab® is recognized as a certified global leader in medical biotechnologies, specializing in cellular therapies. In the United States, RegenLab® USA provides expertly designed Class II medical devices for the preparation of platelet rich plasma from the patient's own blood. Regen® A-PRP® was developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.
Product
Quality
patient
Safety
A-PRP
Efficacy
About Us
Since 2003, RegenLab® has been committed to the development of a unique expertise in the design and manufacturing of high-quality medical devices, intended for the preparation of cellular therapies and autologous platelet-rich plasma (PRP) from the patient's own blood. Bringing these technologies to the United States in 2013, RegenLab® USA offers Regen® A-PRP® and Autologous Thrombin Serum with a focus on product quality, patient safety, and preparation efficiency.
Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. In 2017, a new Good Manufacturing Practice (GMP) facility was completed in Mont-sur-Lausanne, Switzerland (canton of Vaud) allowing RegenLab® to increase access to autologous cellular therapies around the world. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.
